Marissa Dean, MD
Neurology · Birmingham, ALNPI 1376807008
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,250 of the $3,536 with a category attached, or 63.6%. Neurocrine Biosciences, Inc. accounts for 71.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $2,382 and has fallen 84.4% since, to $372 in 2025.
Across 23 payments — averaging $153.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$3K
- Teva Pharmaceuticals USA, Inc.$478
- Insightec,inc$180
- AbbVie$94
- Genentech USA, Inc.$91
- Acadia Pharmaceuticals Inc$90
- plus $73 from 2 others
Across 28 payments — averaging $21,007 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$450K
- Neurocrine Biosciences, Inc.$87K
- PTC Therapeutics, Inc.$44K
- Alnylam Pharmaceuticals Inc.$8K
What the payments were for
- Consulting fees$2,25064%
- Food & beverage$1,28636%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 10 | $2,531 |
| Teva Pharmaceuticals USA, Inc. | 6 | $478 |
| Insightec,inc | 1 | $180 |
| AbbVie | 1 | $94 |
| Genentech USA, Inc. | 1 | $91 |
| Acadia Pharmaceuticals Inc | 2 | $90 |
| Hoffmann-la Roche Limited | 1 | $39 |
| Intrabio Inc | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$2,250
- Austedo XR$217
- AUSTEDO$108
How this compares
$3,536 in reported general payments places this provider in the 55th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 127 | $1,147,417 |
| NuplazidPimavanserin Tartrate | 15 | $100,973 |
| NeuproRotigotine | 18 | $17,530 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 164 | $8,004 |
| Entacapone | 28 | $4,316 |
| RytaryCarbidopa/Levodopa | 11 | $3,903 |
| AmantadineAmantadine Hcl | 43 | $2,434 |
| RivastigmineRivastigmine Tartrate | 19 | $2,244 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 52 | $2,081 |
| Tetrabenazine | 20 | $1,465 |
| Primidone | 36 | $1,239 |
| Rasagiline Mesylate | 15 | $1,199 |
| Propranolol Hcl ErPropranolol Hcl | 12 | $1,152 |
| Bupropion XlBupropion Hcl | 27 | $988 |
| Ropinirole Hcl | 34 | $629 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $478 | $1,147,417127 claims |
| Acadia Pharmaceuticals IncNuplazid | $90 | $100,97315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 255 neurology providers in Alabama.
Other neurology in Birmingham
- Diane CounceBirmingham$895K
- Emily RiserBirmingham$231K
- Wesley KingBirmingham$167K
- Jerzy SzaflarskiBirmingham$164K
- Victor SungBirmingham$138K
- Raymond FaughtBirmingham$99K
- David GeldmacherBirmingham$99K
- David StandaertBirmingham$82K
- Richard DiethelmBirmingham$65K
- Mina LobbousBirmingham$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.